Open Label Randomized Clinical Trial to Assess the Safety of Teleconsultation
ECASeT
1 other identifier
interventional
2,136
1 country
3
Brief Summary
Randomized-controlled trial to assess the safety of remote consultations (both video and teleconsultation) in the follow-up of patients in the hospital setting. A total of 2136 patients will be randomly allocated into one of the three study arms: A) face-to-face consultation (control) B) Remote consultation (telephone or video consultation). Primary outcome will be the frequency of complications of the underlying disease, including adverse reactions to the treatment of the underlying disease. To be eligible for remote consultation, patients have to have adequate digital literacy at physician discretion, technological capacity to use the video conferencing software, and undergo a type of follow-up that, due to the moderate complexity of the pathology, do not require physical examinations. Patients followed up in more than three departments, those with visual or hearing impairments that may hamper patient-physician communication, and those enrolled in another clinical trial that requires an experimental intervention during the follow-up will be excluded from the study. Physicians can schedule and cancel appointments at their discretion. At least three visits should be scheduled in the study setting: the baseline visit (i.e., screening visit), intermediate visits (pre-defined by the physician based on the follow-up needed for managing the baseline condition), and the final visit (i.e., either the follow-up visit closest to 12 ± 2 months after enrollment or before in case of discharge or early discontinuation). The primary objective will be assessed using a non-inferiority analysis of the cumulative incidence of complications of the baseline disease between remote consultation (video and teleconsultation arms) and face-to-face consultation, using a non-inferiority margin of 2%. The analysis will be based on a modified binomial test to assess the non-inferiority of an experimental intervention vs. a control group in a three-arm trial. The primary analysis will be conducted on a per-protocol study sample, which will include all participants who have finished the study and have not been withdrawn because of non-allowed visits using modalities other than scheduled.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Dec 2021
Longer than P75 for not_applicable
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 3, 2021
CompletedFirst Posted
Study publicly available on registry
October 26, 2021
CompletedStudy Start
First participant enrolled
December 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
June 25, 2025
June 1, 2025
4.7 years
October 3, 2021
June 23, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Complications of the underlying disease
Frequency of complications of the underlying disease, including adverse reactions to the treatment of the underlying disease
12 months
Secondary Outcomes (8)
Severe complications of the baseline disease
12 months
Treatment Serious Adverse Event
12 months
Avoidable hospitalizations
12 months
Number of unscheduled medical contacts
12 months
Care process indicators
12 months
- +3 more secondary outcomes
Study Arms (2)
Face-to-face consultation
OTHERRemote consultation (telephone or video consultation mode)
ACTIVE COMPARATORInterventions
Participants will be scheduled with face-to-face appointments as usual (control arm). All phone calls (except reminders for scheduled visits) performed by the physician during the study will be recorded. Per protocol, participants allocated in the control arm can receive up to 25% of physician-doctor interactions by phone (that is, one phone call allowed for three face-to-face appointments).
Patients will be seen through one of the two remote consultation modalities: video consultation or telephone. Patients will receive a reminder by text or call before the appointment. In the case of telephone consultation, patients will be informed of the date and time slot in which they must wait for the doctor's call. At the time of the appointment, the doctor will call the contact phone number of the patients and/or their family members, starting with the first contact number that appears in the patient's medical history, and using the rest of the contacts available if there is no response. . In the case of video consultation, at the time of the appointment, patients will receive a link to the application that manages the teleconsultation. Once in the application, they will remain in the virtual waiting room until the doctor switches to the videoconference.
Eligibility Criteria
You may qualify if:
- Men and women of any age.
- Possibility of making consultations by telephone, at the discretion of the investigator, taking into account the severity and complexity of the baseline pathology and the objective of health care.
- Forecast to carry out follow-up in external consultation.
- Agreement to be attended through a non-face-to-face system.
- Ability to connect to the video consultation system.
- Device compatible with the video consultation system.
- Possibility of collaborating in the necessary evaluations.
- Legal capacity to give informed consent.
You may not qualify if:
- Need to carry out physical examinations, visualize the patient in person or perform techniques that involve face-to-face visits.
- Need for face-to-face consultation due patient's clinical situation.
- Follow-up by more than three medical specialists.
- Visual, hearing or functional impairments that may hamper patient-physician communication.
- Patients enrolled in another clinical trial that requires an experimental intervention during the follow-up.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Hospital Residència Sant Camil
Sant Pere de Ribes, Barcelona, 08810, Spain
Hospital Comarcal de l'Alt Penedès
Vilafranca del Penedès, Barcelona, 08720, Spain
Centre de Rehabilitació
Vilanova i la Geltrú, Barcelona, 08800, Spain
Related Publications (1)
Rodriguez-Molinero A, Carot-Sans G, Escrig R, Tebe C, Arce J, Perez-Lopez C, Ballesta S, Verdejo G, Cedeno A, Riera-Pagespetit M, Vivas-Angeles S, Alarcon JL, Navarro I, Toro S, Mateo L, Torres AJ, Delmas G, Camell H, Chamero A, Gasol M, Piera-Jimenez J; ECASeT Research Group. Study protocol of a randomized controlled trial to assess safety of teleconsultation compared with face-to-face consultation: the ECASeT study. Trials. 2023 Dec 8;24(1):797. doi: 10.1186/s13063-023-07679-1.
PMID: 38066614DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 3, 2021
First Posted
October 26, 2021
Study Start
December 1, 2021
Primary Completion (Estimated)
July 31, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
June 25, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share